Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 339

1.

[Organ preservation by chemoradiation for bladder cancer].

Durdux C, Fabiano E, Méjean A.

Cancer Radiother. 2019 Aug 7. pii: S1278-3218(19)30291-4. doi: 10.1016/j.canrad.2019.06.005. [Epub ahead of print] French.

PMID:
31400955
2.

Fraley's syndrome: a rare cause of obstruction of the collecting system.

Grinholtz D, Méjean A, Audenet F.

Urology. 2019 Aug 1. pii: S0090-4295(19)30695-8. doi: 10.1016/j.urology.2019.07.025. [Epub ahead of print]

PMID:
31377257
3.

A preoperative nomogram to predict major complications after robot assisted partial nephrectomy (UroCCR-57 study).

Khene ZE, Peyronnet B, Bernhard JC, Kocher NJ, Vaessen C, Doumerc N, Pradere B, Seisen T, Beauval JB, Verhoest G, Roumiguié M, De la Taille A, Bruyere F, Roupret M, Mejean A, Mathieu R, Shariat S, Raman JD, Bensalah K; members of the French Committee of Urologic Oncology (CCAFU).

Urol Oncol. 2019 Sep;37(9):577.e1-577.e7. doi: 10.1016/j.urolonc.2019.05.007. Epub 2019 Jun 8.

PMID:
31186143
4.

Tumor Cells Hijack Macrophage-Produced Complement C1q to Promote Tumor Growth.

Roumenina LT, Daugan MV, Noé R, Petitprez F, Vano YA, Sanchez-Salas R, Becht E, Meilleroux J, Clec'h BL, Giraldo NA, Merle NS, Sun CM, Verkarre V, Validire P, Selves J, Lacroix L, Delfour O, Vandenberghe I, Thuilliez C, Keddani S, Sakhi IB, Barret E, Ferré P, Corvaïa N, Passioukov A, Chetaille E, Botto M, de Reynies A, Oudard SM, Mejean A, Cathelineau X, Sautès-Fridman C, Fridman WH.

Cancer Immunol Res. 2019 Jul;7(7):1091-1105. doi: 10.1158/2326-6066.CIR-18-0891. Epub 2019 Jun 4.

PMID:
31164356
5.

Individualised Indications for Cytoreductive Nephrectomy: Which Criteria Define the Optimal Candidates?

Larcher A, Wallis CJD, Bex A, Blute ML, Ficarra V, Mejean A, Karam JA, Van Poppel H, Pal SK.

Eur Urol Oncol. 2019 Jul;2(4):365-378. doi: 10.1016/j.euo.2019.04.007. Epub 2019 May 18. Review.

PMID:
31109902
6.

Long-term oncological outcomes of cystic renal cell carcinoma according to the Bosniak classification.

Boissier R, Ouzaid I, Nouhaud FX, Khene Z, Dariane C, Chkir S, Chelly S, Giwerc A, Allenet C, Lefrancq JB, Gimel P, Bodin T, Rioux-Leclercq N, Correas JM, Albiges L, Hetet JF, Bigot P, Bernhard JC, Long JA, Mejean A, Bensalah K; AFU Committee of Urological Oncology.

Int Urol Nephrol. 2019 Jun;51(6):951-958. doi: 10.1007/s11255-019-02085-6. Epub 2019 Apr 12.

PMID:
30977021
7.

Who is dying after nephrectomy for cancer? Study of risk factors and causes of death after analyzing morbidity and mortality reviews (UroCCR-33 study).

Fontenil A, Bigot P, Bernhard JC, Beauval JB, Soulié M, Charles T, Larre S, Salomon L, Azzouzi R, Méjean A, Bensalah K; Cancerology Committee of the French Association of Urology (CCAFU).

Prog Urol. 2019 Apr;29(5):282-287. doi: 10.1016/j.purol.2019.02.009. Epub 2019 Apr 5.

PMID:
30962141
8.

Adverse events associated with currently used medical treatments for cystinuria and treatment goals: results from a series of 442 patients in France.

Prot-Bertoye C, Lebbah S, Daudon M, Tostivint I, Jais JP, Lillo-Le Louët A, Pontoizeau C, Cochat P, Bataille P, Bridoux F, Brignon P, Choquenet C, Combe C, Conort P, Decramer S, Doré B, Dussol B, Essig M, Frimat M, Gaunez N, Joly D, Le Toquin-Bernard S, Méjean A, Meria P, Morin D, N'Guyen HV, Normand M, Pietak M, Ronco P, Saussine C, Tsimaratos M, Friedlander G, Traxer O, Knebelmann B, Courbebaisse M; French Cystinuria Group.

BJU Int. 2019 Feb 24. doi: 10.1111/bju.14721. [Epub ahead of print]

PMID:
30801923
9.

Performing an early systematic Doppler-ultrasound fails to prevent hemorrhagic complications after complex partial nephrectomy.

Dominique I, Dariane C, Fourniol C, Le Guilchet T, Hurel S, Fontaine E, Mandron E, Audenet F, Mejean A, Timsit MO.

Ther Adv Urol. 2019 Feb 15;11:1756287219828966. doi: 10.1177/1756287219828966. eCollection 2019 Jan-Dec.

10.

Position of cytoreductive nephrectomy in the setting of metastatic renal cell carcinoma patients: does the CARMENA trial lead to a paradigm shift?

Dariane C, Timsit MO, Méjean A.

Bull Cancer. 2018 Dec;105 Suppl 3:S229-S234. doi: 10.1016/S0007-4551(18)30377-1.

PMID:
30595151
11.

Fibroblast Growth Factor Receptor-2 Polymorphism rs2981582 is Correlated With Progression-free Survival and Overall Survival in Patients With Metastatic Clear-cell Renal Cell Carcinoma Treated With Sunitinib.

Vanmechelen M, Lambrechts D, Van Brussel T, Verbiest A, Couchy G, Schöffski P, Dumez H, Debruyne PR, Lerut E, Machiels JP, Richard V, Albersen M, Verschaeve V, Oudard S, Méjean A, Wolter P, Zucman-Rossi J, Beuselinck B.

Clin Genitourin Cancer. 2019 Apr;17(2):e235-e246. doi: 10.1016/j.clgc.2018.11.002. Epub 2018 Nov 16.

PMID:
30527746
12.

[French ccAFU guidelines - Update 2018-2020: Management of kidney cancer].

Bensalah K, Albiges L, Bernhard JC, Bigot P, Bodin T, Boissier R, Correas JM, Gimel P, Hetet JF, Long JA, Nouhaud FX, Ouzaïd I, Rioux-Leclercq N, Méjean A.

Prog Urol. 2018 Nov;28(12S):S3-S31. doi: 10.1016/j.purol.2018.09.009. Epub 2018 Oct 26. Review. French.

PMID:
30473002
13.

[French ccAFU guidelines - Update 2018-2020: Adrenal cancer].

Savoie PH, Murez T, Fléchon A, Sèbe P, Rocher L, Camparo P, Morel-Journel N, Ferretti L, Méjean A.

Prog Urol. 2018 Nov;28(12S):S175-S193. doi: 10.1016/j.purol.2018.08.015. Epub 2018 Oct 27. Review. French.

PMID:
30473001
14.

[French ccAFU guidelines - Update 2018-2020: Retroperitoneal sarcoma].

Murez T, Savoie PH, Fléchon A, Durand X, Rocher L, Camparo P, Morel-Journel N, Ferretti L, Sèbe P, Méjean A.

Prog Urol. 2018 Nov;28(12S):S165-S174. doi: 10.1016/j.purol.2018.08.010. Epub 2018 Oct 25. Review. French.

PMID:
30473000
15.

[French ccAFU guidelines - Update 2018-2020: Testicular germ cell tumors].

Murez T, Fléchon A, Savoie PH, Rocher L, Camparo P, Morel-Journel N, Ferretti L, Sèbe P, Méjean A.

Prog Urol. 2018 Nov;28(12S):S147-S164. doi: 10.1016/j.purol.2018.08.002. Epub 2018 Oct 27. Review. French.

PMID:
30472999
16.

[Update 2018-2020 of French ccAFU guidelines - Editorial].

Méjean A, Bensalah K, Murez T, Rouprêt M, Rozet F.

Prog Urol. 2018 Nov;28(12S):S1-S2. doi: 10.1016/j.purol.2018.10.003. Epub 2018 Nov 20. French. No abstract available.

PMID:
30470340
17.

Sunitinib Alone or after Nephrectomy in Renal Cancer.

Escudier B, Thezenas S, Méjean A.

N Engl J Med. 2018 Nov 8;379(19):1878. doi: 10.1056/NEJMc1811532. No abstract available.

PMID:
30403947
18.

[French ccAFU guidelines - Update 2018-2020: Prostate cancer].

Rozet F, Hennequin C, Beauval JB, Beuzeboc P, Cormier L, Fromont-Hankard G, Mongiat-Artus P, Ploussard G, Mathieu R, Brureau L, Ouzzane A, Azria D, Brenot-Rossi I, Cancel-Tassin G, Cussenot O, Rebillard X, Lebret T, Soulié M, Renard Penna R, Méjean A.

Prog Urol. 2018 Nov;28(12S):S79-S130. doi: 10.1016/j.purol.2018.08.011. Epub 2018 Nov 2. Review. French.

PMID:
30392712
19.

[French ccAFU guidelines - Update 2018-2020: Bladder cancer].

Rouprêt M, Neuzillet Y, Pignot G, Compérat E, Audenet F, Houédé N, Larré S, Masson-Lecomte A, Colin P, Brunelle S, Xylinas E, Roumiguié M, Méjean A.

Prog Urol. 2018 Nov;28(12S):S46-S78. doi: 10.1016/j.purol.2018.07.283. Epub 2018 Oct 23. Review. French.

PMID:
30366708
20.

[French ccAFU guidelines - Update 2018-2020: Penile cancer].

Savoie PH, Fléchon A, Morel-Journel N, Murez T, Ferretti L, Camparo P, Rocher L, Sèbe P, Méjean A.

Prog Urol. 2018 Nov;28(12S):S131-S146. doi: 10.1016/j.purol.2018.08.001. Epub 2018 Oct 22. Review. French.

PMID:
30361138
21.

[French ccAFU guidelines - Update 2018-2020: Upper tract urothelial carcinoma].

Rouprêt M, Xylinas E, Colin P, Houédé N, Compérat E, Audenet F, Larré S, Masson-Lecomte A, Pignot G, Brunelle S, Roumiguié M, Neuzillet Y, Méjean A.

Prog Urol. 2018 Nov;28(12S):S32-S45. doi: 10.1016/j.purol.2018.07.284. Epub 2018 Oct 11. Review. French.

PMID:
30318333
22.

[ypT0N0 after neoadjuvant chemotherapy and cystectomy for muscle-invasive bladder cancer: Incidence and prognosis. A review from the Bladder group of the French Committee of Oncology].

Pignot G, Houédé N, Roumiguié M, Audenet F, Brunelle S, Colin P, Compérat E, Larré S, Masson-Lecomte A, Neuzillet Y, Xylinas E, Méjean A, Rouprêt M; les membres du CCAFU Vessie.

Prog Urol. 2018 Oct;28(12):567-574. doi: 10.1016/j.purol.2018.07.003. Epub 2018 Sep 8. Review. French.

PMID:
30205925
23.

Integrative analysis of dysregulated microRNAs and mRNAs in multiple recurrent synchronized renal tumors from patients with von Hippel-Lindau disease.

Gattolliat CH, Couvé S, Meurice G, Oréar C, Droin N, Chiquet M, Ferlicot S, Verkarre V, Vasiliu V, Molinié V, Méjean A, Dessen P, Giraud S, Bressac-De-Paillerets B, Gardie B, Tean Teh B, Richard S, Gad S.

Int J Oncol. 2018 Oct;53(4):1455-1468. doi: 10.3892/ijo.2018.4490. Epub 2018 Jul 19.

24.

Sunitinib Prior to Planned Nephrectomy in Metastatic Renal Cell Carcinoma: Angiogenesis Biomarkers Predict Clinical Outcome in the Prospective Phase II PREINSUT Trial.

Mauge L, Mejean A, Fournier L, Pereira H, Etienne-Grimaldi MC, Levionnois E, Caty A, Abadie-Lacourtoisie S, Culine S, Le Moulec S, Linassier C, Théodore C, Ravaud A, Albiges L, Grine A, Tartour E, Milano G, Gille AS, Verkarre V, Helley D, Oudard S; PREINSUT study group.

Clin Cancer Res. 2018 Nov 15;24(22):5534-5542. doi: 10.1158/1078-0432.CCR-18-1045. Epub 2018 Jul 30.

PMID:
30061359
25.

Secondary bladder exstrophy repair with a bilateral gracilis muscle flap in an adult female patient: Case report of an original procedure.

Schaff JB, Fontaine E, Dariane C, Mejean A, Lantieri L, Hivelin M.

Ann Chir Plast Esthet. 2019 Feb;64(1):120-123. doi: 10.1016/j.anplas.2018.06.008. Epub 2018 Jul 3.

PMID:
29980317
26.

Sunitinib Alone or after Nephrectomy in Metastatic Renal-Cell Carcinoma.

Méjean A, Ravaud A, Thezenas S, Colas S, Beauval JB, Bensalah K, Geoffrois L, Thiery-Vuillemin A, Cormier L, Lang H, Guy L, Gravis G, Rolland F, Linassier C, Lechevallier E, Beisland C, Aitchison M, Oudard S, Patard JJ, Theodore C, Chevreau C, Laguerre B, Hubert J, Gross-Goupil M, Bernhard JC, Albiges L, Timsit MO, Lebret T, Escudier B.

N Engl J Med. 2018 Aug 2;379(5):417-427. doi: 10.1056/NEJMoa1803675. Epub 2018 Jun 3.

27.

The Case | A 69-year-old man with bladder carcinoma and renal lesions.

Isnard P, Tran HM, Le Stang MB, Parize P, Méjean A, Joly D, Correas JM, Rabant M, Zaidan M.

Kidney Int. 2018 Jun;93(6):1493-1494. doi: 10.1016/j.kint.2017.12.024. No abstract available.

PMID:
29792277
28.

Slowdown of surface diffusion during early stages of bacterial colonization.

Vourc'h T, Peerhossaini H, Léopoldès J, Méjean A, Chauvat F, Cassier-Chauvat C.

Phys Rev E. 2018 Mar;97(3-1):032407. doi: 10.1103/PhysRevE.97.032407.

PMID:
29776183
29.

Single-cell genetic analysis validates cytopathological identification of circulating cancer cells in patients with clear cell renal cell carcinoma.

Broncy L, Njima BB, Méjean A, Béroud C, Romdhane KB, Ilie M, Hofman V, Muret J, Hofman P, Bouhamed HC, Paterlini-Bréchot AP.

Oncotarget. 2018 Apr 13;9(28):20058-20074. doi: 10.18632/oncotarget.25102. eCollection 2018 Apr 13.

30.

Contemporary assessment of the correlation between Bosniak classification and histological characteristics of surgically removed atypical renal cysts (UroCCR-12 study).

Nouhaud FX, Bernhard JC, Bigot P, Khene ZE, Audenet F, Lang H, Bergerat S, Fraisse G, Grenier N, Cornelis F, Nedelcu C, Béjar S, Fromont-Hankard G, Allory Y, Lindner V, Verkarre V, Daniel L, Yacoub M, Correas JM, Méjean A, Rioux-Leclercq N, Bensalah K.

World J Urol. 2018 Oct;36(10):1643-1649. doi: 10.1007/s00345-018-2307-6. Epub 2018 May 5.

PMID:
29730837
31.

Nephron sparing surgery in tumours greater than 7cm.

de Saint Aubert N, Audenet F, Mccaig F, Delavaud C, Verkarre V, Le Guilchet T, Dariane C, Pettenati C, Slaoui H, Mejean A, Timsit MO.

Prog Urol. 2018 May;28(6):336-343. doi: 10.1016/j.purol.2018.03.009. Epub 2018 Apr 23.

PMID:
29699856
32.

[French CCAFU guidelines on prostate cancer: hormono-naive metastatic prostate cancer - update 2017].

Rozet F, Hennequin C, Mongiat-Artus P, Beuzeboc P, Beauval JB, Cormier L, Fromont-Hankard G, Ouzzane A, Ploussard G, Renard-Penna R, Méjean A.

Prog Urol. 2018 May;28(6):303-306. doi: 10.1016/j.purol.2018.03.006. Epub 2018 Apr 19. French. No abstract available.

PMID:
29680190
33.

Characterization of CyrI, the hydroxylase involved in the last step of cylindrospermopsin biosynthesis: Binding studies, site-directed mutagenesis and stereoselectivity.

Mazmouz R, Essadik I, Hamdane D, Méjean A, Ploux O.

Arch Biochem Biophys. 2018 Jun 1;647:1-9. doi: 10.1016/j.abb.2018.04.007. Epub 2018 Apr 11.

PMID:
29653078
34.

[Non-palpable testicular tumors in adults: A management based on imaging? Issue from the French Urologic Association Genital Cancer committee's edit].

Rocher L, Feretti L, Camparo P, Savoie PH, Morel-Journel N, Murez T, Sebe P, Flechon A, Méjean A, Durand X.

Prog Urol. 2018 Jun;28(8-9):407-415. doi: 10.1016/j.purol.2018.03.007. Epub 2018 Apr 9. Review. French.

PMID:
29650457
35.

[Tim-3: a novel biomarker and therapeutic target in oncology].

Granier C, Gey A, Dariane C, Mejean A, Timsit MO, Blanc C, Verkarre V, Radulescu C, Fabre E, Vano Y, Oudard S, Badoual C, Tartour É.

Med Sci (Paris). 2018 Mar;34(3):231-237. doi: 10.1051/medsci/20183403011. Epub 2018 Mar 16. Review. French.

36.

Impact of hospital volume and surgeon volume on robot-assisted partial nephrectomy outcomes: a multicentre study.

Peyronnet B, Tondut L, Bernhard JC, Vaessen C, Doumerc N, Sebe P, Pradere B, Guillonneau B, Khene ZE, Nouhaud FX, Brichart N, Seisen T, Alimi Q, Beauval JB, Mathieu R, Rammal A, de la Taille A, Baumert H, Droupy S, Bruyere F, Rouprêt M, Mejean A, Bensalah K; members of the French Committee of Urologic Oncology (CCAFU).

BJU Int. 2018 Jun;121(6):916-922. doi: 10.1111/bju.14175. Epub 2018 Mar 25.

37.

Polymorphisms in the Von Hippel-Lindau Gene Are Associated With Overall Survival in Metastatic Clear-Cell Renal-Cell Carcinoma Patients Treated With VEGFR Tyrosine Kinase Inhibitors.

Verbiest A, Lambrechts D, Van Brussel T, Couchy G, Wozniak A, Méjean A, Lerut E, Oudard S, Verkarre V, Job S, de Reynies A, Machiels JP, Patard JJ, Zucman-Rossi J, Beuselinck B.

Clin Genitourin Cancer. 2018 Aug;16(4):266-273. doi: 10.1016/j.clgc.2018.01.013. Epub 2018 Feb 5.

PMID:
29503246
38.

Simple and complex renal cysts in adults: Classification system for renal cystic masses.

Hélénon O, Crosnier A, Verkarre V, Merran S, Méjean A, Correas JM.

Diagn Interv Imaging. 2018 Apr;99(4):189-218. doi: 10.1016/j.diii.2017.10.005. Epub 2018 Feb 23. Review.

39.

[Comparison of operative and oncologic results between partial nephrectomy and radiofrequency ablation for treatment of renal tumors in patients older than 75].

Cholley I, Correas JM, Masson-Lecomte A, Sanchez S, Champy C, Le Guilchet T, Ariane M, Hurel S, Audenet F, Thiounn N, Fontaine E, Mejean A, Timsit MO.

Prog Urol. 2018 Jan;28(1):55-61. doi: 10.1016/j.purol.2017.10.006. Epub 2017 Nov 22. French.

PMID:
29174691
40.

[Sporadic kidney cancer of young subjects: Study of the clinical and pathological features of a bicentric cohort].

Cohen J, Timsit MO, Zerbib OD, Rouprêt M, Verkarre V, Comperat E, Mejean A, Bitker MO.

Prog Urol. 2018 Feb;28(2):94-106. doi: 10.1016/j.purol.2017.10.007. Epub 2017 Nov 21. French.

PMID:
29170016
41.

[Retrospective comparison of the reproducibility and the performances of R.E.N.A.L. score, 12 segments score and UPRCC score for the partial nephrectomy].

Gury-Coupier L, Audenet F, Delavaud C, Timsit MO, Mejean A.

Prog Urol. 2017 Dec;27(16):1050-1057. doi: 10.1016/j.purol.2017.09.007. Epub 2017 Oct 31. French.

PMID:
29097040
42.

Pro-angiogenic gene expression is associated with better outcome on sunitinib in metastatic clear-cell renal cell carcinoma.

Beuselinck B, Verbiest A, Couchy G, Job S, de Reynies A, Meiller C, Albersen M, Verkarre V, Lerut E, Méjean A, Patard JJ, Laguerre B, Rioux-Leclercq N, Schöffski P, Oudard S, Zucman-Rossi J.

Acta Oncol. 2018 Apr;57(4):498-508. doi: 10.1080/0284186X.2017.1388927. Epub 2017 Nov 2.

PMID:
29095068
43.

Pathological heterogeneity in sporadic synchronous renal tumors: Is the histological concordance predictable?

Beaugerie A, Audenet F, Verkarre V, Delavaud C, Le Guilchet T, Hurel S, de Saint Aubert N, Correas JM, Fontaine E, Richard S, Méjean A, Timsit MO.

Urol Oncol. 2018 Jan;36(1):11.e7-11.e12. doi: 10.1016/j.urolonc.2017.09.002. Epub 2017 Oct 6.

PMID:
28993058
44.

Midterm Outcomes of 12 Renal Transplant Recipients Treated With Eculizumab to Prevent Atypical Hemolytic Syndrome Recurrence.

Levi C, Frémeaux-Bacchi V, Zuber J, Rabant M, Devriese M, Snanoudj R, Scemla A, Amrouche L, Mejean A, Legendre C, Sberro-Soussan R.

Transplantation. 2017 Dec;101(12):2924-2930. doi: 10.1097/TP.0000000000001909.

PMID:
28858176
45.

[Advancement in the treatment of renal carcinoma].

Méjean A.

Nephrol Ther. 2017 May;13(3):154-159. doi: 10.1016/j.nephro.2017.02.008. French.

PMID:
28527565
46.

Biphasic Squamoid Alveolar Renal Cell Carcinoma: 2 Cases in a Family Supporting a Continuous Spectrum With Papillary Type I Renal Cell Carcinoma.

Chartier S, Méjean A, Richard S, Thiounn N, Vasiliu V, Verkarre V.

Am J Surg Pathol. 2017 Jul;41(7):1011-1012. doi: 10.1097/PAS.0000000000000870. No abstract available.

PMID:
28498286
47.

Prospective assessment and histological analysis of adherent perinephric fat in partial nephrectomies.

Dariane C, Le Guilchet T, Hurel S, Audenet F, Beaugerie A, Badoual C, Tordjman J, Clément K, Urien S, Pietak M, Fontaine E, Méjean A, Timsit MO.

Urol Oncol. 2017 Feb;35(2):39.e9-39.e17. doi: 10.1016/j.urolonc.2016.09.008. Epub 2016 Oct 27.

PMID:
28341496
48.

Ablative Therapies for Renal Tumors: Patient Selection, Treatment Planning, and Follow-Up.

Correas JM, Delavaud C, Gregory J, Le Guilchet T, Lamhaut L, Timsit MO, Méjean A, Hélénon O.

Semin Ultrasound CT MR. 2017 Feb;38(1):78-95. doi: 10.1053/j.sult.2016.11.009. Epub 2016 Dec 1. Review.

PMID:
28237283
49.

What is the significance of end-stage renal disease risk estimation in living kidney donors?

Gaillard F, Baron S, Timsit MO, Eladari D, Fournier C, Prot-Bertoye C, Bertocchio JP, Lamhaut L, Friedlander G, Méjean A, Legendre C, Courbebaisse M.

Transpl Int. 2017 Aug;30(8):799-806. doi: 10.1111/tri.12931. Epub 2017 Mar 5.

50.

Immunothérapie dans les cancers de la prostate.

Oudard S, Thibault C, Angelergues A, Tartour E, Timsit MO, Mejean A, Michel C, Vano Y.

Bull Cancer. 2016 Nov;103 Suppl 1:S144-S150. doi: 10.1016/S0007-4551(16)30372-1. French.

PMID:
28057178

Supplemental Content

Loading ...
Support Center